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Abstract 57 
Background & Aims: Surgical trauma leads to an inflammatory response that causes 58 
surgical morbidity. Reduced antioxidant micronutrient (AM)a levels and/or excessive 59 
levels of Reactive Oxygen Species (ROS)b have previously been linked to delayed wound 60 
healing and presence of chronic wounds. We aimed to evaluate the effect of pre-operative 61 
supplementation with encapsulated fruit and vegetable juice powder concentrate 62 
(JuicePlus+®) on postoperative morbidity and Quality of Life (QoL)c. 63 
Methods: We conducted a randomised, double-blind, placebo-controlled two-arm parallel 64 
clinical trial evaluating postoperative morbidity following lower third molar surgery. 65 
Patients aged between 18 and 65 years were randomised to take verum or placebo for 10 66 
weeks prior to surgery and during the first postoperative week. The primary endpoint was 67 
the between-group difference in QoL over the first postoperative week, with secondary 68 
endpoints being related to other measures of postoperative morbidity (pain and trismus). 69 
Results: One-hundred and eighty-three out of 238 randomised patients received surgery 70 
(Intention-To-Treat population). Postoperative QoL tended to be higher in the active 71 
compared to the placebo group (p=0.059). Furthermore, reduction in mouth opening 2 72 
days after surgery was 3.1 mm smaller (p=0.042), the mean pain score over the 73 
postoperative week was 9.4 mm lower (p=0.007) and patients were less likely to 74 
experience moderate to severe pain on postoperative day 2 (RR 0.58, p=0.030), 75 
comparing verum to placebo groups. 76 
Conclusion: Pre-operative supplementation with a fruit and vegetable supplement rich in 77 
AM may improve postoperative QoL and reduce surgical morbidity and post-operative 78 
complications after surgery.  79 
Registered under ClinicalTrials.gov Identifier no. NCT01145820 80 
 81 
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Keywords 82 
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Introduction  85 
Surgical removal of lower third molars (wisdom teeth) is one of the most common 86 
surgical procedures. It is associated with marked postoperative morbidity as a 87 
consequence of surgical trauma, including pain, swelling and reduced mouth opening 88 
(trismus) (1, 2). Whilst it is recognised that there is significant inter-individual variability 89 
in postoperative morbidity, patient-level determinants remain poorly understood. 90 
Reactive Oxygen Species (ROS)b released by inflammatory cells, in particular 91 
neutrophils, play a key role in wound healing, with normal ROS levels facilitating 92 
healing, and excess ROS creating oxidative stress. Oxidative stress activates major redox-93 
regulated pro-inflammatory signalling cascades via the redox-sensitive gene transcription 94 
factor Nuclear Factor kappa-B (NFkB), and thus the redox status of healing tissues and 95 
their constituent cells impacts upon wound healing dynamics (3, 4). A wide variety of 96 
antioxidant micronutrients (AM)a are implicated in regulating the redox environment 97 
during wound healing. Excess ROS are removed by various antioxidant systems working 98 
in concert via redox cycling reactions, such as vitamins E, C and the non-radical 99 
tripeptide, Reduced Glutathione (GSH)d, the terminal stage of which results in the 100 
oxidation of GSH to its oxidized counterpart GSSGe (5). GSH however, must be 101 
synthesised by cells, a process that requires the activation of the redox-regulated gene 102 
transcription factor Nuclear Factor E2 (Erythroid 2)-Related Factor 2 (NRF2)f (6, 7). 103 
Whole food nutrition rather than individual vitamin supplementation is therefore 104 
generally recommended in order to maintain AM in homeostatic balance and preserve 105 
GSH, which is a powerful regulator of cellular redox state and thus of key transcriptional 106 
events. In acute models of rodent wound healing, tissue levels of GSH, ascorbate and 107 
vitamin E show a sustained decrease of 60-70% after wounding (8). Furthermore, tissue 108 
levels of AM are considerably reduced in the wounds of aged rats relative to young rats 109 
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(9), and in immunosuppressed rats compared with immunocompetent animals (10). Thus, 110 
impaired healing appears to be associated with reduced AM tissue levels known to affect 111 
key redox-regulated signalling pathways, such as NRF2 and NFkB.  112 
Given the role of ROS in wound healing and control of infection, there is a surprising 113 
paucity of data on the effect of AM intake and wound healing, including the incidence of 114 
post-surgical complications/morbidity. Therefore, here we report a double-blind, placebo-115 
controlled, randomised clinical trial to ascertain the efficacy of pre-operative 116 
supplementation with encapsulated fruit and vegetable juice powder concentrate to reduce 117 
postoperative morbidity and improve QoL following lower third molar surgery.  118 
 119 
Materials and Methods 120 
Study design and participants 121 
The FAVOURITE study was a randomised, double-blind, placebo-controlled two-arm 122 
parallel clinical trial conducted at the The School of Dentistry, University of Birmingham 123 
and Birmingham Dental Hospital, Birmingham, UK. The study protocol was approved by 124 
the South Staffordshire Local Research Ethics Committee (Reference 09/H1203/82). All 125 
enrolled patients provided written informed consent. 126 
The objective of this study was to evaluate whether encapsulated fruit and vegetable 127 
powder concentrate (JuicePlus+®, NSA Inc., Collierville, Tennessee, USA) 128 
supplementation, beginning 10 weeks before surgery, improved postoperative QoL and 129 
reduced postoperative morbidity and complications following lower third molar surgery 130 
compared to placebo.  131 
Patients aged between 18 and 65 years who required the surgical removal of one 132 
mandibular third molar were considered eligible to participate. Patients on long term 133 
antimicrobial or anti-inflammatory drugs or taking any vitamin or mineral supplements, 134 
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patients requiring pre-operative antibiotic prophylaxis, patients with allergies to any of the 135 
ingredients contained in the active or placebo capsules, patients with a self-reported 136 
inability to swallow the supplied capsules, an inability or unwillingness to give informed 137 
consent, patients requiring additional concomitant tooth extractions at the time of surgery, 138 
pregnant or lactating women, and patients with any clinically significant or unstable 139 
physical or mental condition or disability were excluded from the trial. 140 
 141 
Randomisation and allocation concealment 142 
At the baseline visit, following written informed consent and verification of eligibility 143 
criteria, eligible patients were assigned the next available randomisation number and then 144 
provided with the corresponding supplements. Randomisation was carried out using block 145 
randomisation with variable block size in a 1:1 ratio using a computer algorithm 146 
[www.randomization.com]. Test and placebo capsules were provided to the study centre 147 
in consecutively numbered, identical tubs. Both patients and clinicians were blinded to 148 
group assignment. The randomisation list was not kept at the study centre and was not 149 
accessible by investigators during the study.  150 
 151 
Intervention 152 
The verum test capsules were based on commercially available formulations of Juice 153 
Plus+® (active, F&Vg) and contained a fine, granular powder, encapsulated in a size 00 154 
gelatine capsule. The capsule contained a blended fruit and vegetable pulp and juice 155 
powder concentrate derived from Acerola cherry, apple, beet, beetroot, broccoli, cabbage, 156 
carrot, cranberry, dates, garlic, kale, orange, peach, papaya, parsley, pineapple, prune, 157 
spinach, sugar beet, tomato, with Spirulina pacifica, Lactobacillus acidophilus, rice bran, 158 
oat bran and Dunaliella salina. These active ingredients were supplemented to provide 159 
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declared totals (daily dose) of β-Carotene (7.5 mg), vitamin E (46 mg), vitamin C 160 
(200 mg) and folic acid (400 µg). The amount of polyphenolic AM contained within the 161 
phytonutrient capsules varies according to growing and harvest conditions, and absolute 162 
levels were not analysed. The placebo (control) capsules were of identical appearance and 163 
contained microcrystalline cellulose. 164 
Patients were asked to take two capsules, twice daily with food (= four supplements per 165 
day) for 10 weeks prior to their surgical intervention. Following wisdom tooth surgery, 166 
participants were asked to continue taking the study medication for the first postoperative 167 
week. 168 
Capsule counts were performed on the day of surgery and at the final study visit, when all 169 
remaining capsules were returned to the study centre. 170 
 171 
Surgery and follow-up 172 
Patients had standard outpatient third molar surgery ten weeks following randomisation 173 
(see online supplement for details on surgical procedure). Patients received a 174 
postoperative diary after the surgical intervention to record analgesic consumption and 175 
pain intensity on a 10cm Visual Analogue Scale (VAS)h once daily for one week. 176 
Additionally, patients were clinically examined two days and one week (final study visit) 177 
following surgery (see Study Flow Chart, Figure 1). 178 
 179 
Outcome measures 180 
Postoperative QoL was the primary outcome and was determined at the 1-week follow-up 181 
visit using the Postoperative Symptom and Severity (PoSSe)i scale, a self-administered, 182 
validated instrument specifically designed to evaluate QoL over the first postoperative 183 
week following third molar surgery. The instrument measures QoL in seven domains 184 
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(subscales), including eating, speech, sensation, appearance, pain, sickness and 185 
interference with daily activities. The overall score is a weighted sum of the subscale 186 
scores, ranging from 0-100 with higher scores indicating worse QoL (2). 187 
Secondary outcomes of morbidity and post-operative complications included (i) trismus, 188 
which represents the reduction in a patient’s mouth opening postoperatively compared to 189 
baseline, (ii) pain intensity during the first postoperative week, and (iii) analgesic 190 
consumption. 191 
Mouth opening was measured by the clinician as the inter-incisal distance in mm before 192 
surgery and on postoperative day 2 and day 7 using a ruler. Pain intensity and analgesic 193 
consumption were recorded by the patient in the patient diary.  194 
 195 
Other data and laboratory analyses 196 
Recorded demographic and anthropometric data included age, gender, race/ethnicity, 197 
smoking status, weight, height and Body Mass Index (BMI)j. We assessed a number of 198 
tooth- and surgery-related measures on the day of surgery (see online supplement for 199 
details). Venous blood samples were taken, processed and stored at all visits for the 200 
analysis of a range of micronutrients at the end of the study. Details regarding blood 201 
sampling and laboratory procedures are described in the online supplement. We estimated 202 
small molecule antioxidant capacity (SMAC)k in serum from serum concentrations of uric 203 
acid and vitamins A, C and E for baseline and day of surgery as previously described 204 
(11). 205 
 206 
Statistical analyses 207 
Primary endpoint and sample size 208 
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The primary endpoint was the between group difference in oral health-related QoL over 209 
the first postoperative week assessed with the PoSSe scale. The study required a 210 
minimum of 170 patients (n=85 per group) in order to achieve 90% power to detect a 211 
standardised effect size of 0.5 at a significance level of α=0.05, which would generally be 212 
considered a clinically meaningful difference in QoL between groups (12). Subjects lost 213 
to follow-up were replaced until the target sample size for the primary endpoint was 214 
reached. 215 
 216 
Secondary endpoints 217 
Assessment of the following secondary endpoints was performed: 218 
• Specific QoL domains (PoSSe subscales), 219 
• Trismus on postoperative day 2 and day 7, i.e., the difference between the pre-220 
operative interincisal distance on the day of surgery and the interincisal distance 221 
two days and seven days following surgery, respectively, 222 
• Mean pain score from postoperative days one to six, 223 
• The proportion of patients that reported pain of 50mm or higher on day 2 and day 224 
6, 225 
• The proportion of patients experiencing an absolute increase of 20mm in pain 226 
score on any day between postoperative day 4 and day 6, compared to the previous 227 
day (a surrogate for alveolar osteitis/wound infection),  228 
• The between-group difference in total consumption of analgesics during the first 229 
post-operative week, 230 
• Adverse Events (AEs)l. 231 
 232 
Pre-specified analysis plan 233 
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Statistical analysis was performed according to a pre-specified analysis plan (see online 234 
supplement for details). Briefly, analyses were done according to the Intention-To-Treat 235 
(ITT)o principle, which included all randomised patients who received the supplements 236 
and returned for at least one follow-up appointment. Summary statistics were calculated 237 
as appropriate. For comparisons between groups for primary and secondary endpoints we 238 
calculated effect estimates, 95% confidence intervals and p-values for using appropriate 239 
multiple regression models. In addition to unadjusted estimates, we calculated estimates 240 
adjusting for important baseline characteristics only and estimates adjusting for important 241 
baseline as well as surgical characteristics. Further details, including the handling of 242 
missing data, are described in the online supplement.  243 
 244 
Compliance 245 
Compliance was calculated for patients for whom follow-up capsule counts were 246 
available as the proportion of capsules taken relative to the expected number of capsules 247 
taken with 100% compliance. ‘Good compliance’ was defined as at least 80% of capsules 248 
taken (13, 14). 249 
 250 
Results 251 
Baseline characteristics 252 
Randomised patients 253 
Patients were enrolled between June 2010 and October 2013. A total of 248 patients were 254 
assessed for eligibility. Eight patients did not meet the inclusion criteria and two patients 255 
withdrew consent. Therefore, 238 participants were randomised out of which 120 256 
belonged to the active and 118 to the placebo group (Figure 1). Baseline characteristics of 257 
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all randomised patients were overall well balanced between the two treatment arms 258 
(Table 1). 259 
 260 
ITT population 261 
Of the 238 randomized patients, 19 patients allocated to F&V and 26 patients allocated to 262 
placebo did not return for surgery. Therefore, surgery was performed in 193 participants. 263 
A further ten patients (active n=3, placebo n=7) did not return for any follow-up 264 
appointments. Hence, 183 patients had data available for at least one endpoint (ITT 265 
population) (Figure 1). Detailed descriptions of patients lost to follow-up and missing 266 
data can be found in the Online Supplemental Material. Briefly, current smokers were less 267 
likely to attend for surgery, and patients with poor oral hygiene and less extensive surgery 268 
were less likely to attend for follow-up after surgery (Supplemental Table 1). Due to 269 
some patients not recording all required details in their postoperative diary, not returning 270 
their diary, or some participants not attending one of their follow-up appointments, some 271 
endpoint analyses contained less than 183 patient data (Figure 1). Further details on 272 
missing data are presented in Supplemental Table 2. 273 
Baseline and surgical characteristics of the ITT population were overall well balanced 274 
(Error! Reference source not found.2). However, the proportion of current smokers 275 
(29.6% vs 15.3%) and plasma vitamin C concentrations at baseline (61.4 µmol/L vs 52.9 276 
µmol/L) were higher, and bone removal was lower (minor bone removal in 28.2% vs. 277 
43.9%) in the active compared to the placebo group, respectively. 278 
 279 
Compliance 280 
On average, patients took more than 80% of the assigned capsules. There were no 281 
statistically significant differences between active and placebo groups in terms of 282 
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compliance (Supplemental Table 3). Thirteen patients stopped taking the capsules 283 
because of AEs (placebo=7, F&V=6). 284 
 285 
Main results 286 
Primary endpoint 287 
PoSSe scale data was available for 172 patients (Table 3) and showed that, on average, 288 
patients in the active intervention group (mean 33.8, SD 15.5) reported less postoperative 289 
morbidity during the first postoperative week than patients in the placebo group (mean 290 
38.4, SD 16.4, unadjusted mean difference in PoSSe score: -4.59 , 95% CIp: -9.37 to 0.18, 291 
p=0.059). When the treatment effect estimate was adjusted for baseline age, BMI, gender, 292 
race, and smoking status, the mean difference between PoSSe scores was -5.57 points 293 
(95% CI: -10.48 to -0.66, p=0.027). 294 
Additional adjustment for surgical characteristics, i.e. amount of bone removal, length of 295 
surgery, tooth sectioning, and pre-operative chlorhexidine rinse, rendered a mean 296 
difference between PoSSe scores of -3.97 for active compared to placebo group (95% CI: 297 
-8.79 to 0.84, p=0.105). 298 
 299 
Secondary endpoints 300 
Comparing active to placebo groups, the analysis of separate PoSSe domains shows 301 
significantly lower impact for pain in unadjusted analyses, and significantly lower 302 
impacts for pain, eating and sickness in analyses adjusted for baseline characteristics. 303 
Following adjustments for surgical characteristics, none of the differences between 304 
subscale impacts were statistically significant (Table 3). Trismus (limitation of mouth 305 
opening) on postoperative day 2 was lower in the active intervention compared to placebo 306 
group by -3.1mm (95% CI: -6.1 to -0.1, p=0.042). Adjustment for baseline characteristics 307 
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resulted in -3.7mm (95% CI: -6.6, 0.7, p=0.016). However, additional adjustment for 308 
surgical factors resulted in an attenuated difference in trismus between groups (-2.7mm, 309 
95% CI -5.6 to 0.2, p=0.069) (Table 3). One week following surgery, the estimate of a 310 
difference in trismus between active and placebo decreased to less than 1.5mm and 311 
showed no statistical significance for any analysis. 312 
The mean pain score for postoperative days 1 to 6 also revealed a statistically significant 313 
difference between groups in all analyses, with a higher mean pain score by a mean of 314 
8.5mm for the control group compared to the active group when adjusting for both 315 
baseline and surgical factors (95% CI -15.5 to -1.6, p=0.017). The conclusion was the 316 
same after imputation. 317 
There was a 46% lower risk of VAS score over 50% on follow-up day 2 in the active 318 
group after adjusting for baseline and surgical covariates with a 95% CI 0.32 to 0.89, 319 
which was statistically significant at the 5% significance level (p=0.015). 320 
Other secondary outcomes were not statistically significantly different at the 5% 321 
significance level between treatment groups (Table 3). 322 
 323 
Micronutrient levels 324 
The levels of vitamin C, α-Tocopherol, α-Carotene, and β-Carotene were statistically 325 
significantly higher in the F&V group compared to placebo, following 10 weeks of 326 
supplementation and having adjusted for their respective baseline levels (Table 4). For 327 
active compared to placebo between baseline and surgery, the mean difference in vitamin 328 
C was 23.6µmol/L (95% CI 17.1 to 30.1, p<0.001), the mean difference for β-Carotene 329 
was 1.13µmol/L (95% CI 0.88 to 1.38, p<0.001), the mean difference for α-Tocopherol 330 
was 2.86µmol/L (95% CI 1.69 to 4.05, p<0.001), and the mean difference in α-Carotene 331 
was 0.02µmol/L (95% CI 0.00 to 0.03, p=0.045). For these AMs, the treatment effect 332 
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estimates were also statistically significant at day 2 and day 7 for active compared to 333 
placebo after adjusting for the baseline levels. There were no statistically significant 334 
differences between treatment groups for the other micronutrients. Estimated serum 335 
SMAC was significantly higher in the active compared to the placebo group at the time of 336 
surgery. 337 
 338 
Adverse events 339 
In total 14 AEs, which were classified as having a “possible” or “probable” relationship 340 
with the intervention, were recorded. The vast majority of these (n=11) were 341 
gastrointestinal (GI)q upset, mainly nausea and bloating. Other possible AEs were 342 
“itchiness” (n=2) and “tiredness” (n=1). All of the patients with GI upset stopped taking 343 
the supplements, as did one patient with itchiness (50%) and the one patient with reported 344 
tiredness.  Overall, 57% of AEs were reported in the placebo group (GI upset n=5 (45%), 345 
itchiness n=2 (100%), tiredness n=1 (100%)).  346 
 347 
Discussion 348 
Clinical research on the effect of perioperative nutritional supplementation on wound 349 
healing has focussed mainly on critically ill patients and/or patients with chronic wounds, 350 
such as pressure ulcers (15). Although the role of AMs in wound healing is widely 351 
recognised (16), there is a paucity of data on the potential effect of micronutrient 352 
supplementation on the healing of surgical wounds. Lower third molar surgery is a very 353 
common surgical procedure associated with significant postoperative morbidity and is 354 
also an attractive surgical model for clinical research (17-20). Postoperative sequelae 355 
include pain, swelling, trismus (reduced mouth opening) for several days and occur as a 356 
result of the inflammatory response to the surgical trauma to bone and soft tissues as well 357 
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as the microbial challenge to the intraoral wound. These sequelae lead to functional 358 
incapacity affecting QoL. This randomised, double-blind, placebo-controlled clinical trial 359 
examined whether the pre- and perioperative intake of a commercially available fruit and 360 
vegetable pulp and juice powder concentrate (Juice Plus+®) was associated with 361 
improved QoL and reduced morbidity postoperatively. The results suggest that the 362 
intervention may have a modest benefit in terms of overall QoL, trismus and 363 
postoperative pain.   364 
These results need to be cautiously interpreted in light of the limitations of this study. 365 
Firstly, the supplements evaluated in the present study are made from a wide variety of 366 
different fruit and vegetables and are enriched with carotenoids and vitamins. It is 367 
therefore unclear which specific constituents or combination of constituents would be 368 
responsible for any observed effect. However, evidence suggests that the beneficial 369 
effects of higher fruit and vegetable consumption on inflammatory diseases are 370 
attributable to the additive and synergistic interactions of the plethora of phytochemicals 371 
present in whole foods by targeting multiple signal transduction pathways (21), and these 372 
mechanisms could be underpinnig the effects observed in the present study. The 373 
supplements evaluated here have been shown to contain a substantial amount of different 374 
(poly)phenolic compounds, demonstrating that the capsules preserve these compounds as 375 
they occur in the large variety of source plants used in their manufacture (22). 376 
Alternatively, the observed effect may be attributable to a few or a single specific 377 
constituent. Serum concentrations of α-tocopherol, β-carotene and vitamin C increased 378 
significantly over 10 weeks of supplement intake in the active group, and marked 379 
differences between groups in the plasma concentrations of these micronutrients were 380 
evident at the time of surgery, resulting in higher estimated small molecule antioxidant 381 
capacity in serum (Table 4). However, whether or not the observed effects are a result of 382 
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increased antioxidant capacity is uncertain, and future research would ideally assess 383 
markers of oxidative stress in the local wound environment. Vitamin C plays a crucial 384 
role in various wound healing processes (16, 23), and emerging evidence suggests that 385 
vitamin C, possibly in concert with vitamin E, may have antinociceptive effects, as 386 
demonstrated in different pain models (24-27). Recent clinical studies suggest that 387 
administration of vitamin C can alleviate inflammatory pain, including postoperative pain 388 
(28-30). In the present study, the strongest effects were observed for the secondary pain 389 
endpoints, with patients in the verum group being almost half as likely to experience 390 
moderate to severe pain 2 days after surgery than patients in the placebo group, and 391 
reduced pain levels could directly or indirectly explain the effects on other endpoints. 392 
Secondly, the observed p-values for the primary endpoint, as well as several secondary 393 
endpoints hover around the 5% significance level, depending on if and what baseline and 394 
surgical characteristics are included in the statistical models. In the absence of anchor-395 
based estimates of a minimally important difference in QoL following third molar 396 
surgery, the sample size was set to achieve 90% power to detect a standardised effect size 397 
of 0.5 (12). However, research on other patient reported outcomes suggests that 398 
standardised effect sizes of 0.2-0.3 would represent small but important, i.e., clinically 399 
significant differences (31). The effect sizes observed in this trial for QoL (including the 400 
eating, sickness and pain subscales) and the secondary endpoints of pain and trismus were 401 
in that range or slightly larger. However, our study lacked power to detect differences 402 
smaller than 0.5 and the possibility that the observed differences are due to chance must 403 
be acknowledged. 404 
Loss to follow-up before surgery was relatively high at 19%, but was unlikely to be 405 
related to the intervention and cannot have been related to the study outcomes as these 406 
patients did not receive surgery. Current smoking was the only baseline characteristic that 407 
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was significantly associated with patients not attending for surgery, possibly a marker of 408 
lower compliance, which has also been reported in the context of observational research 409 
(32-34). Our secondary analyses adjusted for surgical factors deemed important for 410 
surgical morbidity, including markers of surgical complexity/severity of trauma (bone 411 
removal, tooth sectioning, duration of surgery) and pre-operative chlorhexidine rinse (35). 412 
While these are variables collected after randomisation, the difficulty of surgery/surgical 413 
trauma or decision to use pre-operative chlorhexidine rinse cannot have reasonably been 414 
affected by group assignment in this double-blind trial, and these statistical adjustments 415 
allow appreciation of the effect of chance differences between groups. As can be expected 416 
for a moderately sized trial, some imbalances were observed at baseline, including a 417 
moderately higher vitamin C concentration in the active group. In a post-hoc sensitivity 418 
analysis, adjustment for baseline vitamin C concentrations yielded similar estimates 419 
(results not shown). 420 
Finally, patients in the present study received supplements for a relatively long period of 421 
10 weeks preoperatively. Nutritional supplement formulations such as the one evaluated 422 
in this study are usually taken long-term, and in the absence of short-term 423 
pharmacokinetic data we were confident that steady state would be achieved by 10 weeks 424 
(36). However, such preoperative supplementation for 10 weeks would be difficult or 425 
impossible to implement in many clinical scenarios, and short-term supplementation 426 
should therefore be evaluated in future studies. Notwithstanding these uncertainties and 427 
limitations, our results should encourage further research into the possible effects of 428 
nutritional supplements and their constituents on postsurgical pain, morbidity and wound 429 
healing. In conclusion, perioperative supplementation with a commercially available fruit 430 
and vegetable pulp and juice powder concentrate (Juice Plus+®) may reduce 431 
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postoperative morbidity and improve QoL during recovery after lower third molar 432 
surgery.   433 
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Table 1: Baseline patient characteristics and micronutrient levels by treatment group. 
 Placebo (n=118) F&V (n=120) 
Age, years 26 [24, 32] 28 [24, 34] 
Male, n (%) 40 (33.9) 49 (40.8) 
Smoking Status, n (%)   
Never 63 (53.4) 63 (52.5) 
Ex-smoker 27 (22.9) 23 (19.2) 
Current smoker 28 (23.7) 34 (28.3) 
Index of multiple deprivation 34.7 (18.2) 33.6 (18.1) 
Systolic Blood Pressure (mmHg) 127.3 (13.0) 128.1 (14.8) 
Diastolic Blood Pressure (mmHg) 79.0 (12.4) 79.6 (10.8) 
Weight (kg) 75.2 (18.9) 76.4 (16.8) 
Height (m) 1.69 (0.11) 1.70 (0.10) 
BMI 25.1 [21.8, 28.9] 25.4 [22.2, 30.1] 
Race, n (%)   
White 72 (61.0) 79 (65.8) 
Asian 30 (25.4) 22 (18.3) 
Black 9 (7.6) 12 (10.0) 
Other 7 (5.9) 7 (5.8) 
Micronutrients*   
Vitamin C (µmol/L) 55.2 (25.0) 60.1 (26.4) 
Lutein (µmol/L) 0.19 [0.14, 0.25] 0.20 [0.15, 0.26] 
Zeaxanthin (µmol/L) 0.05 [0.04, 0.07] 0.05 [0.04, 0.07] 
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Cryptoxanthin (µmol/L) 0.10 [0.07, 0.17] 0.10 [0.08, 0.15] 
Lycopene (µmol/L) 0.87 [0.55, 1.19] 0.76 [0.55, 1.10] 
α-Carotene (µmol/L) 0.08 [0.04, 0.12] 0.08 [0.05, 0.11] 
β-Carotene (µmol/L) 0.29 [0.18, 0.46] 0.32 [0.23, 0.52] 
α-Tocopherol (µmol/L) 20.2 (4.6) 20.9 (5.8) 
Retinol (µmol/L) 1.33 (0.33) 1.28 (0.34) 
SMAC (µmol/L Teq) 381 [330, 441] 385 [346, 457] 
Continuous variables are presented as mean (SD) or median [IQR]. 
* There is missing baseline data for all micronutrients for 13 patients assigned to placebo and 
13 patients assigned to F&V. 
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Table 2: Baseline patient characteristics, surgical characteristics, and micronutrient levels by 
treatment group for those that received surgery and returned for at least one follow-up 
appointment. 
 Placebo (n=85) F&V (n=98) 
Age, years 28 [24, 33] 28.5 [23, 34] 
Male, n (%) 32 (37.7) 39 (40.0) 
Smoking Status, n (%)   
Never 54 (63.5) 56 (57.1) 
Ex-smoker 18 (21.2) 13 (13.3) 
Current smoker 13 (15.3) 29 (29.6) 
Index of multiple deprivation 35.5 (18.1) 33.6 (17.2) 
Systolic Blood Pressure (mmHg) 128.0 (13.5) 127.2 (14.3) 
Diastolic Blood Pressure (mmHg) 80.4 (12.5) 79.2 (10.3) 
Weight (kg) 76.0 (18.9) 75.9 (17.0) 
Height (m) 1.70 (0.11) 1.71 (0.09) 
BMI 25.1 [22.2, 29.0] 24.7 [22.0, 29.5] 
Race, n (%)   
White 51 (60.0) 66 (67.4) 
Asian 23 (27.1) 19 (19.4) 
Black 7 (8.2) 7 (7.1) 
Other 4 (4.7) 6 (6.1) 
Baseline micronutrients*   
Vitamin C (µmol/L) 52.9 (24.3) 61.4 (27.1) 
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Lutein (µmol/L) 0.19 [0.14, 0.25] 0.20 [0.15, 0.26] 
Zeaxanthin (µmol/L) 0.05 [0.04, 0.07] 0.05 [0.04, 0.07] 
Cryptoxanthin (µmol/L) 0.09 [0.07, 0.17] 0.11 [0.08, 0.16] 
Lycopene (µmol/L) 0.91 [0.55, 1.18] 0.77 [0.57, 1.10] 
α-Carotene (µmol/L) 0.08 [0.04, 0.13] 0.08 [0.06, 0.11] 
β-Carotene (µmol/L) 0.31 [0.18, 0.52] 0.32 [0.25, 0.52] 
α-Tocopherol (µmol/L) 19.0 [16.4, 23.1] 20.0 [17.0, 23.4] 
Retinol (µmol/L) 1.23 [1.06, 1.49] 1.25 [1.01, 1.48] 
SMAC (µmol/l Teq) 382 [325, 447] 383 [346, 441] 
Surgical measures   
Bone removal, n(%)   
Minor 24 (28.2) 43 (43.9) 
Moderate 49 (57.7) 47 (48.0) 
Severe 12 (14.1) 8 (8.2) 
Oral Hygiene   
Good/Very good 70 (82.4) 85 (86.7) 
Fair/Poor/Very poor 13 (15.3) 10 (10.2) 
Missing 2 (2.3) 3 (3.1) 
Length of surgery (minutes) 13 [9, 20] 12 [8, 17] 
Tooth sectioning, n(%) 57 (67.1) 54 (55.1) 
Pre-operative CHX rinse, n(%) 42 (49.4) 45 (45.9) 
Lingual flap, n(%) 22 (25.9) 18 (18.4) 
Envelope flap, n(%) 50 (58.8) 61 (62.2) 
Continuous variables are presented as mean (SD) or median [IQR]. 
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* There is missing baseline data for all micronutrients for 2 patients assigned to placebo and 4 
patients assigned to F&V. 
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Table 3: Comparison of standardised PoSSe score at 7 days post-surgery, PoSSe subscale 
scores and other secondary outcomes between treatment groups. 
 Unadjusted treatment 
effect estimate (95% 
CI), p-value 
Adjusted treatment effect 
estimate (95% CI), p-
value$ 
Adjusted treatment 
effect estimate (95% 
CI), p-valueβ 
PoSSe score at 
7 days post-
surgery 
-4.6 (-9.4 to 0.2), 
p=0.059 
-5.6 (-10.5 to -0.7), 
p=0.027 
-4.0 (-8.8 to 0.8), 
p=0.105 
PoSSe  
subscales:  
Eating -0.25 (-0.55 to 0.05), 
0.098 
-0.32 (-0.63 to -0.02), 
0.04 
-0.23 (-0.53 to 0.07), 
0.128 
Speech -0.10 (-0.40 to 0.20), 
0.526 
-0.10 (-0.40 to 0.20), 
0.517 
-0.08 (-0.39 to 0.23), 
0.609 
Sensation -0.17 (-0.32 to 0.28), 
0.910 
-0.03 (-0.32 to 0.27), 
0.867 
0.01 (-0.30 to 0.31), 
0.953 
Appearance -0.16 (-0.46 to 0.14), 
0.286 
-0.22 (-0.54 to 0.09), 
0.158 
-0.14 (-0.45 to 0.18), 
0.395 
Pain -0.31 (-0.61 to -0.01), 
0.041 
-0.33 (-0.64 to -0.02), 
0.038 
-0.26 (-0.58 to 0.33), 
0.110 
Sickness -0.22 (-0.52 to 0.08), 
0.151 
-0.31 (-0.61 to -0.16), 
0.039 
-0.26 (-0.56 to 0.05), 
0.099 
Interaction -0.21 (-0.51 to 0.08), 
0.159 
-0.24 (-0.55 to 0.08), 
0.137 
-0.15 (-0.46 to 0.15), 
0.322 
Trismus at day 
2 (mm)† 
-3.11 (-6.11 to -0.11), 
0.042 
-3.66 (-6.63 to -0.68), 
0.016 
-2.70 (-5.61 to 0.21), 
0.069 
Trismus at day 
7 (mm)† 
-1.43 (-4.50 to 1.64), 
0.360 
-1.85 (-5.01 to 1.30), 
0.247 
-0.50 (-3.57 to 2.57), 
0.749 
Mean pain 
score for days 
-8.49 (-15.2 to -1.81), 
0.013 
-9.31 (-16.2, -2.43), 
0.008 
-8.51 (-15.5 to -1.55), 
0.017 
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1 to 6† 
Total 
consumption 
of analgesics 
(day 1 to 6)† 
-2.27 (-5.85 to 1.31), 
0.212 
-3.02 (-6.64 to 0.60), 
0.101 
-2.38 (-6.11 to 1.36), 
0.211 
Proportion 
patients pain 
score>50% 
VAS on day 
2α 
0.58 (0.35 to 0.95), 
0.030 
0.54 (0.33 to 0.90), 0.017 
0.54 (0.32 to 0.89), 
0.015 
Proportion 
patients pain 
score>50% 
VAS on day 
6α 
0.72 (0.40 to 1.28), 
0.259 
0.65 (0.37 to 1.14), 0.133 
0.71 (0.40 to 1.24), 
0.227 
Proportion of 
patients with 
absolute 
increase of 
20% on VAS 
on any day 
from day 4 to 
day 6, 
compared to 
the previous 
dayα 
0.55 (0.29 to 1.06), 
0.073 
0.56 (0.28 to 1.10), 0.092 
0.60 (0.30 to 1.20), 
0.149 
 
Outcome measure is presented as mean (SD), n, or median [IQR], n, or a/b (%). PoSSe 
subscales are standardised to have SD=1.  
$: Treatment effect estimate is adjusted for smoking, age, gender, ethnicity and BMI. 
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β: Treatment effect estimate adjusted for smoking status, age, gender, ethnicity and BMI, and 
amount of bone removal, length of surgery, tooth sectioning, and pre-operative chlorhexidine 
rinse.  
†: Linear regression model.  
α: Poisson regression model so treatment effect estimate is a risk ratio.  
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Table 4: Effect of treatment on micronutrient levels 
 
Placebo 
 
Active 
 
Mean difference (95% 
CI), p-value 
Vitamin C, µmol/L 
Surgery 54.0 [31.4, 70.5] 80.7 [62.5, 98.6] 23.6 (17.1 to 30.1), <0.001 
2-day post-op review 49.1 [26.1, 68.4] 74.8 [61.9, 92.5] 23.1 (16.2 to 30.0), <0.001 
7-day post-op review 46.8 [26.9, 66.3] 76.1 [59.6, 93.0] 24.1 (17.5 to 30.8), <0.001 
α-Tocopherol, µmol/L 
Surgery 19.7 [16.7, 22.9] 22.8 [19.6, 28.1] 2.86 (1.69 to 4.05), <0.001 
2-day post-op review 18.7 [16.4, 21.6] 21.9 [19.1, 27.2] 2.57 (1.53 to 3.62), <0.001 
7-day post-op review 19.7 [16.3, 22.1] 23.2 [20.0, 28.0] 3.14 (2.10 to 4.17), <0.001 
β-Carotene, µmol/L 
Surgery 0.31 [0.18, 0.44] 1.11 [0.55, 1.95] 1.13 (0.88 to 1.38), <0.001 
2-day post-op review 0.28 [0.17, 0.44] 1.08 [0.58, 1.82] 1.04 (0.82 to 1.27), <0.001 
7-day post-op review 0.27 [0.18, 0.44] 1.15 [0.51, 1.74] 1.04 (0.81 to 1.27), <0.001 
α-Carotene, µmol/L 
Surgery 0.08 [0.05, 0.11] 0.08 [0.06, 0.12] 0.02 (0.00 to 0.03), 0.045 
2-day post-op review 0.07 [0.04, 0.11] 0.08 [0.06, 0.12] 0.02 (0.00 to 0.03), 0.024 
7-day post-op review 0.07 [0.04, 0.11] 0.08 [0.06, 0.12] 0.02 (0.00 to 0.03), 0.037 
Retinol, µmol/L 
Surgery 1.28 [1.01, 1.48] 1.26 [1.05, 1.49] 0.05 (-0.01 to 0.10), 0.102 
2-day post-op review 1.07 [0.86, 1.30] 1.08 [0.92, 1.32] 0.05 (-0.01 to 0.11), 0.080 
7-day post-op review 1.20 [0.99, 1.38] 1.25 [1.01, 1.49] 0.06 (-0.00 to 0.13), 0.061 
Lutein, µmol/L 
Surgery 0.19 [0.15, 0.26] 0.20 [0.14, 0.26] -0.02 (-0.03 to 0.00), 0.061 
2-day post-op review 0.18 [0.14, 0.24] 0.19 [0.13, 0.24] -0.01 (-0.03 to 0.00), 0.130 
7-day post-op review 0.18 [0.14, 0.24] 0.19 [0.14, 0.24] -0.01 (-0.02 to 0.01), 0.374 
Lycopene, µmol/L 
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Surgery 0.80 [0.54, 1.17] 0.74 [0.52, 1.01] 0.02 (-0.07 to 0.11), 0.670 
2-day post-op review 0.78 [0.56, 1.13] 0.72 [0.49, 0.97] 0.00 (-0.10 to 0.10), 0.980 
7-day post-op review 0.73 [0.50, 1.13] 0.65 [0.49, 1.04] -0.03 (-0.14 to 0.07), 0.534 
Cryptoxanthin, µmol/L 
Surgery 0.11 [0.07, 0.17] 0.11 [0.07, 0.19] 0.02 (-0.01 to 0.05), 0.180 
2-day post-op review 0.10 [0.06, 0.16] 0.11 [0.07, 0.19] 0.02 (-0.00 to 0.05), 0.111 
7-day post-op review 0.10 [0.06, 0.15] 0.10 [0.08, 0.19] 0.03 (0.00 to 0.05), 0.020 
Zeaxanthin, µmol/L 
Surgery 0.06 [0.04, 0.07] 0.05 [0.04, 0.07] -0.00 (-0.01 to 0.01), 0.874 
2-day post-op review 0.05 [0.04, 0.07] 0.05 [0.04, 0.06] 0.00 (-0.01 to 0.01), 0.955 
7-day post-op review 0.05 [0.04, 0.07] 0.05 [0.04, 0.06] 0.00 (-0.00 to 0.01), 0.489 
SMAC, µmol/l Teq 
Surgery 364 [317, 422] 388 [338, 451] 
18.4 (4.2 to 32.6), 
0.012 
 
Day of surgery n=82 for placebo and n=93 for active;  
day 2 n=79 for placebo and n=92 for active;  
day 7 n=78 for placebo and n=82 for active.  
Treatment effect is adjusted for baseline measurements of micronutrient levels. 
SMAC – Small molecule antioxidant capacity, micromoles of Trolox equivalents/litre (μ
mol/l Teq) 
SMAC not available for postoperative day 2 and day 7. 
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Figure Legends: 
Figure 1: CONSORT flow diagram 
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Analysed (n=98) 
 No PoSSe data (n=5) 
 No trismus data on day 2 
(n=5) 
 No trismus data on day 7 
Analysed (n=85) 
 No PoSSe data (n=4) 
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 No trismus data on day 7 
Analysis (n=183) 
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